Canntab Therapeutics Limited Stock Probability of Future Pink Sheet Price Finishing Under 1.0E-4
| CTABF Stock | USD 0.0001 0.00 0.00% |
Canntab |
Canntab Therapeutics Target Price Odds to finish below 1.0E-4
The tendency of Canntab Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move below current price in 90 days |
| 0.0001 | 90 days | 0.0001 | about 34.62 |
Based on a normal probability distribution, the odds of Canntab Therapeutics to move below current price in 90 days from now is about 34.62 (This Canntab Therapeutics Limited probability density function shows the probability of Canntab Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon Canntab Therapeutics Limited has a beta of -2.68 suggesting as returns on its benchmark rise, returns on holding Canntab Therapeutics Limited are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Canntab Therapeutics is expected to outperform its benchmark. Additionally Canntab Therapeutics Limited has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Canntab Therapeutics Price Density |
| Price |
Predictive Modules for Canntab Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Canntab Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Canntab Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Canntab Therapeutics is not an exception. The market had few large corrections towards the Canntab Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Canntab Therapeutics Limited, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Canntab Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.13 | |
β | Beta against Dow Jones | -2.68 | |
σ | Overall volatility | 0.0007 | |
Ir | Information ratio | -0.13 |
Canntab Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Canntab Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Canntab Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Canntab Therapeutics generated a negative expected return over the last 90 days | |
| Canntab Therapeutics has high historical volatility and very poor performance | |
| Canntab Therapeutics has some characteristics of a very speculative penny stock | |
| Canntab Therapeutics Limited has accumulated 126.2 K in total debt with debt to equity ratio (D/E) of 2.43, implying the company greatly relies on financing operations through barrowing. Canntab Therapeutics has a current ratio of 0.56, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Canntab Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Canntab Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Canntab Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Canntab to invest in growth at high rates of return. When we think about Canntab Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 293.36 K. Net Loss for the year was (3.69 M) with loss before overhead, payroll, taxes, and interest of (939.01 K). | |
| Canntab Therapeutics Limited has accumulated about 691.11 K in cash with (2.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 15.0% of Canntab Therapeutics shares are held by company insiders |
Canntab Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Canntab Pink Sheet often depends not only on the future outlook of the current and potential Canntab Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Canntab Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 38.9 M |
Canntab Therapeutics Technical Analysis
Canntab Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Canntab Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Canntab Therapeutics Limited. In general, you should focus on analyzing Canntab Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Canntab Therapeutics Predictive Forecast Models
Canntab Therapeutics' time-series forecasting models is one of many Canntab Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Canntab Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Canntab Therapeutics
Checking the ongoing alerts about Canntab Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Canntab Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Canntab Therapeutics generated a negative expected return over the last 90 days | |
| Canntab Therapeutics has high historical volatility and very poor performance | |
| Canntab Therapeutics has some characteristics of a very speculative penny stock | |
| Canntab Therapeutics Limited has accumulated 126.2 K in total debt with debt to equity ratio (D/E) of 2.43, implying the company greatly relies on financing operations through barrowing. Canntab Therapeutics has a current ratio of 0.56, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Canntab Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Canntab Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Canntab Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Canntab to invest in growth at high rates of return. When we think about Canntab Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 293.36 K. Net Loss for the year was (3.69 M) with loss before overhead, payroll, taxes, and interest of (939.01 K). | |
| Canntab Therapeutics Limited has accumulated about 691.11 K in cash with (2.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 15.0% of Canntab Therapeutics shares are held by company insiders |
Other Information on Investing in Canntab Pink Sheet
Canntab Therapeutics financial ratios help investors to determine whether Canntab Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Canntab with respect to the benefits of owning Canntab Therapeutics security.